Paris‑based AI health startup Lucis has closed a $20 million Series A, led by venture firm General Catalyst. The round also includes other backers and marks the YC‑alumni’s first institutional financing. Lucis’ platform promises in the preventative diagnostics powered by large‑language models, positioning it against traditional symptom‑check apps. The market for AI‑enabled preventative care is projected to exceed $5 billion by 2028, attracting major pharma interest.

The funding arrives as European health systems scramble for cost‑saving AI tools, and Lucis claims its early‑warning engine can flag chronic‑disease risk before symptoms appear. Existing investors such as Kima Ventures and local angel networks see the capital as a catalyst to scale clinical trials and integrate with insurers. Regulators in France have recently eased data‑privacy rules for clinical AI, facilitating faster deployment.

With the fresh capital, Lucis plans to broaden its data partnerships across hospitals and launch a subscription service for employers seeking employee wellness insights. The deal values the company at roughly €150 million, underscoring investor confidence in AI‑driven prevention. The round signals growing appetite for tech‑enabled health risk management. It also gives Lucis runway to pursue regulatory approvals in France and Germany, where preventive health reimbursement schemes are expanding soon. The subscription model targets corporate wellness budgets, a segment growing 12% annually.